Median Technologies will be participating in the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from 30th May - 2nd June, McCormick Place, Chicago, IL, USA.
Bachem has announced investment across their site network, with new funding to improve production facilities at their Bubendorf, Vista and St Helens sites, along with a new site in Sisseln.
Medicover Genetics, an innovator in genetic diagnostics and laboratory enablement, has announced the integration of Element Biosciences’ AVITI sequencing system into its end-to-end genomics platform.
Biocon Biologics, a fully integrated global biosimilars company and subsidiary of Biocon, has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation in the United Kingdom (UK) for YESINTEK.
Selvita is the first contract research organisation (CRO) to license a Chemical Protein Stability Assay developed and patented by Medicines Discovery Catapult (MDC) to help identify and prioritise drug candidates faster.
Process industry software specialist, eschbach, has won the German Innovation Award for its use of artificial intelligence (AI) to drive productivity and efficiency in the chemical and pharmaceutical industries.
Lonza, a contract development and manufacturing organisation (CDMO), has announced the launch of its new Design2Optimize platform to enhance process development and manufacturing of small molecule APIs.
Cinclus Pharma Holding has announced an agreement with Zentiva, a European pharmaceutical company, for the commercialisation and manufacturing of its lead asset, linaprazan glurate, in Europe.
Shilpa Biologicals, a full-service contract development and manufacturing organisation (CDMO), announces the opening of a dedicated bioconjugation suite at its Dharwad site in India.
The CryoPod Carrier from Azenta Life Sciences is designed to provide a safe, portable, and trackable solution for hand carrying temperature-sensitive materials between labs, providing protection below -150°C for over 3 hours.
Kaida BioPharma, an earlystage pharma company dedicated to advancing targeted anti-cancer therapies to address hormone-driven cancers affecting women, has entered into a manufacturing agreement with Northway Biotech, for the manufacturing of KAD101.
